A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Oedema Secondary to CRVO

Trial Profile

A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Oedema Secondary to CRVO

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2014

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Retinal vein occlusion
  • Focus Therapeutic Use
  • Sponsors Eyetech Pharmaceuticals
  • Most Recent Events

    • 21 Jun 2014 New trial record
    • 18 Jan 2007
    • 24 Aug 2005
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top